Royalty Pharma plc Net Income (Loss) Available to Common Stockholders, Diluted
Royalty Pharma plc (RPRX) reported Net Income (Loss) Available to Common Stockholders, Diluted of $22.28 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Income Statement › Net Income
us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted · last filed 2026-08-05
- Royalty Pharma plc net income (loss) available to common stockholders, diluted for the quarter ending 2026-06-30 was $22.28M, a 46.78% decline year-over-year.
- Royalty Pharma plc net income (loss) available to common stockholders, diluted for the quarter ending 2026-03-31 was $375.22M, a 18.70% increase year-over-year.
- Royalty Pharma plc net income (loss) available to common stockholders, diluted for the quarter ending 2025-12-31 was $278.11M, a 1.04% increase year-over-year.
- Royalty Pharma plc net income (loss) available to common stockholders, diluted for the quarter ending 2025-09-30 was $372.39M, a 48.23% decline year-over-year.
- Royalty Pharma plc net income (loss) available to common stockholders, diluted for fiscal 2025 was $1.01B, a 11.48% decline from fiscal 2024.
- Royalty Pharma plc net income (loss) available to common stockholders, diluted for fiscal 2024 was $1.14B, a 25.64% decline from fiscal 2023.
- Royalty Pharma plc net income (loss) available to common stockholders, diluted for fiscal 2023 was $1.53B, a 3466.40% increase from fiscal 2022.
- Royalty Pharma plc net income (loss) available to common stockholders, diluted for fiscal 2022 was $42.83M, a 93.09% decline from fiscal 2021.
| Period end | Net Income (Loss) Available to Common Stockholders, Diluted 3 month | Net Income (Loss) Available to Common Stockholders, Diluted 3 month as first filed | Net Income (Loss) Available to Common Stockholders, Diluted 6 month | Net Income (Loss) Available to Common Stockholders, Diluted 6 month as first filed | Net Income (Loss) Available to Common Stockholders, Diluted 9 month | Net Income (Loss) Available to Common Stockholders, Diluted 12 month |
|---|---|---|---|---|---|---|
| 2026-06-30 | $22.28M 10-Q · filed 2026-08-05 | $398.17M 10-Q · filed 2026-08-05 | $675.62M derived: sum of 3 quarters · filed 2026-08-05 | $1.05B derived: sum of 4 quarters · filed 2026-08-05 | ||
| 2026-03-31 | $375.22M 10-Q · filed 2026-05-06 | $653.34M derived: sum of 2 quarters · filed 2026-05-06 | $1.03B derived: sum of 3 quarters · filed 2026-05-06 | $1.07B derived: sum of 4 quarters · filed 2026-08-05 | ||
| 2025-12-31 | $278.11M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-11 | $650.50M derived: sum of 2 quarters · filed 2026-02-11 | $692.38M derived: sum of 3 quarters · filed 2026-08-05 | $1.01B 10-K · filed 2026-02-11 | ||
| 2025-09-30 | $372.39M 10-Q · filed 2025-11-05 | $414.26M derived: sum of 2 quarters · filed 2026-08-05 | $727.41M 10-Q · filed 2025-11-05 | $1.01B derived: sum of 4 quarters · filed 2026-08-05 | ||
| 2025-06-30 | $41.87M 10-Q · filed 2026-08-05 | $39.87M 10-Q · filed 2025-08-06 | $357.98M 10-Q · filed 2026-08-05 | $354.98M 10-Q · filed 2025-08-06 | $633.24M derived: sum of 3 quarters · filed 2026-08-05 | $1.35B derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | $316.11M 10-Q · filed 2026-05-06 | $315.11M 10-Q · filed 2025-05-08 | $591.37M derived: sum of 2 quarters · filed 2026-05-06 | $1.31B derived: sum of 3 quarters · filed 2026-05-06 | $1.45B derived: sum of 4 quarters · filed 2026-05-06 | |
| 2024-12-31 | $275.26M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-11 | $994.65M derived: sum of 2 quarters · filed 2026-02-11 | $1.13B derived: sum of 3 quarters · filed 2026-02-11 | $1.14B 10-K · filed 2026-02-11 | ||
| 2024-09-30 | $719.39M 10-Q · filed 2025-11-05 | $854.30M derived: sum of 2 quarters · filed 2025-11-05 | $860.61M 10-Q · filed 2025-11-05 | $1.52B derived: sum of 4 quarters · filed 2026-02-11 | ||
| 2024-06-30 | $134.91M 10-Q · filed 2025-08-06 | $141.23M 10-Q · filed 2025-08-06 | $802.93M derived: sum of 3 quarters · filed 2026-02-11 | $899.10M derived: sum of 4 quarters · filed 2026-02-11 | ||
| 2024-03-31 | $6.32M 10-Q · filed 2025-05-08 | $668.02M derived: sum of 2 quarters · filed 2026-02-11 | $764.19M derived: sum of 3 quarters · filed 2026-02-11 | $1.07B derived: sum of 4 quarters · filed 2026-02-11 | ||
| 2023-12-31 | $661.71M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-11 | $757.87M derived: sum of 2 quarters · filed 2026-02-11 | $1.06B derived: sum of 3 quarters · filed 2026-02-11 | $1.53B 10-K · filed 2026-02-11 | ||
| 2023-09-30 | $96.17M 10-Q · filed 2024-11-06 | $401.84M derived: sum of 2 quarters · filed 2024-11-06 | $865.86M 10-Q · filed 2024-11-06 | $215.49M derived: sum of 4 quarters · filed 2025-02-12 | ||
| 2023-06-30 | $305.67M 10-Q · filed 2024-08-08 | $769.69M 10-Q · filed 2024-08-08 | $119.32M derived: sum of 3 quarters · filed 2025-02-12 | $316.37M derived: sum of 4 quarters · filed 2025-02-12 | ||
| 2023-03-31 | $464.01M 10-Q · filed 2024-05-09 | -$186.35M derived: sum of 2 quarters · filed 2025-02-12 | $10.69M derived: sum of 3 quarters · filed 2025-02-12 | $434.42M derived: sum of 4 quarters · filed 2025-02-12 | ||
| 2022-12-31 | -$650.37M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-12 | -$453.32M derived: sum of 2 quarters · filed 2025-02-12 | -$29.59M derived: sum of 3 quarters · filed 2025-02-12 | $42.83M 10-K · filed 2025-02-12 | ||
| 2022-09-30 | $197.05M 10-Q · filed 2023-11-08 | $620.77M derived: sum of 2 quarters · filed 2023-11-08 | $693.20M 10-Q · filed 2023-11-08 | $407.00M derived: sum of 4 quarters · filed 2024-02-15 | ||
| 2022-06-30 | $423.73M 10-Q · filed 2023-08-08 | $496.15M 10-Q · filed 2023-08-08 | $209.96M derived: sum of 3 quarters · filed 2024-02-15 | $354.48M derived: sum of 4 quarters · filed 2024-02-15 | ||
| 2022-03-31 | $72.42M 10-Q · filed 2023-05-09 | -$213.77M derived: sum of 2 quarters · filed 2024-02-15 | -$69.25M derived: sum of 3 quarters · filed 2024-02-15 | $584.49M derived: sum of 4 quarters · filed 2024-02-15 | ||
| 2021-12-31 | -$286.19M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-15 | -$141.67M derived: sum of 2 quarters · filed 2024-02-15 | $512.06M derived: sum of 3 quarters · filed 2024-02-15 | $619.73M 10-K · filed 2024-02-15 | ||
| 2021-09-30 | $144.52M 10-Q · filed 2022-11-08 | $798.26M derived: sum of 2 quarters · filed 2022-11-08 | $905.92M 10-Q · filed 2022-11-08 | $1.08B derived: sum of 4 quarters · filed 2023-02-15 | ||
| 2021-06-30 | $653.74M 10-Q · filed 2022-08-04 | $761.40M 10-Q · filed 2022-08-04 | $932.50M derived: sum of 3 quarters · filed 2023-02-15 | $1.22B derived: sum of 4 quarters · filed 2023-02-15 | ||
| 2021-03-31 | $107.66M 10-Q · filed 2022-05-05 | $278.76M derived: sum of 2 quarters · filed 2023-02-15 | $569.39M derived: sum of 3 quarters · filed 2023-02-15 | $602.86M derived: sum of 4 quarters · filed 2023-02-15 | ||
| 2020-12-31 | $171.09M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-15 | $461.73M derived: sum of 2 quarters · filed 2023-02-15 | $495.20M derived: sum of 3 quarters · filed 2023-02-15 | $495.20M 10-K · filed 2023-02-15 | ||
| 2020-09-30 | $290.63M 10-Q · filed 2020-11-12 | $324.10M derived: sum of 2 quarters · filed 2020-11-12 | $324.10M 10-Q · filed 2020-11-12 | |||
| 2020-06-30 | $33.47M 10-Q · filed 2020-08-12 | $33.47M 10-Q · filed 2020-08-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |